by mobi | May 1, 2025
Yes, your company is responsible for reporting if it manufactures or markets products in the Italian healthcare sector, regardless of having a physical presence in Italy. It's advisable to designate a local representative to manage compliance and communication...
by mobi | May 1, 2025
Previously, only members of industry associations like Farmindustria were required to disclose such information, often in aggregate form. The new Act supersedes these voluntary codes, enforcing mandatory, individual-level disclosures for a broader range of companies,...
by mobi | May 1, 2025
The Italian Sunshine Act (Law No. 62/2022) mandates pharmaceutical, medical device, and other healthcare-related companies to publicly disclose financial relationships with healthcare professionals (HCPs) and healthcare organizations (HCOs). This initiative aims to...
by mobi | May 1, 2025
Al momento, il modello ufficiale di segnalazione è in attesa di rilascio. Le aziende dovrebbero monitorare gli aggiornamenti del Ministero della Salute e preparare i propri sistemi interni per allinearsi ai requisiti che verranno stabiliti.
by mobi | May 1, 2025
Sì. La legge richiede la divulgazione degli accordi che comportano benefici diretti o indiretti per HCPs o HCOs. Pertanto, se una borsa di studio facilita la partecipazione di HCPs a eventi, tali beneficiari devono essere divulgati individualmente.
